acut
lower
respiratori
infect
common
caus
morbid
infant
children
time
requir
intens
care
mechan
ventil
viral
bronchiol
bacteri
pneumonia
account
major
lower
respiratori
tract
infect
lead
respiratori
insuffi
cienci
pediatr
intens
care
admiss
twentyseven
percent
children
requir
mechan
ventil
least
h
pediatr
intens
care
unit
diagnos
bronchiol
diagnosi
pneumonia
median
length
time
intub
acut
pulmonari
infect
lead
respiratori
failur
approxim
day
viral
bronchiol
remain
lead
caus
hospit
admiss
infanc
frequent
caus
acut
respiratori
failur
children
admit
pediatr
intens
care
unit
north
america
pneumonia
children
younger
year
age
annual
incid
karen
power
case
per
commun
acquir
pneumonia
also
lead
sever
respiratori
compromis
especi
children
preexist
diseas
detail
understand
divers
etiolog
distinct
clinic
cours
acut
pulmonari
infect
essenti
pediatr
critic
care
praction
chapter
focu
bronchiol
pneumonia
two
lead
caus
pulmonari
infect
lead
picu
admiss
approxim
one
third
children
develop
bronchiol
fi
rst
year
life
infant
unit
state
requir
hospit
although
hospit
rate
increas
last
three
decad
mortal
remain
low
overal
mortal
rate
high
high
risk
infant
death
occur
infant
younger
month
age
comorbid
prematur
congenit
heart
diseas
congenit
acquir
lung
diseas
immunodefi
cienci
respiratori
syncyti
viru
rsv
fi
rst
isol
still
repres
major
caus
bronchiol
caus
virus
includ
parainfl
uenza
adenoviru
enteroviru
infl
uenza
recent
human
metapneumoviru
human
bocaviru
hbov
northern
hemispher
rsv
outbreak
occur
octob
june
human
metapneumoviru
hmpv
recent
identifi
ed
caus
agent
bronchiol
case
possibl
surpass
parainfl
uenza
second
common
etiolog
preval
slightli
higher
late
winter
spring
parainfl
uenza
infect
peak
month
age
repres
approxim
case
bronchiol
parainfl
uenza
endem
throughout
year
especi
common
late
spring
male
time
like
requir
hospit
bronchiol
like
sever
diseas
xlink
genet
trait
result
reduc
toler
hypoxia
postul
would
consist
observ
increas
mortal
newborn
male
infant
respiratori
distress
syndrom
virtual
children
age
two
infect
rsv
children
age
fi
infect
hmpv
children
age
nine
infect
hbov
remaind
discuss
bronchiol
divid
rsv
nonrsv
bronchiol
although
etiolog
agent
may
differ
clinic
cours
often
similar
respiratori
syncyti
viru
rsv
account
bronchiol
infect
onehalf
infant
within
fi
rst
year
life
hospit
approxim
infant
yearli
affect
infant
approxim
infant
requir
mechan
ventil
coinfect
either
hmpv
rhinoviru
occur
young
children
two
type
rsv
exist
type
b
type
common
believ
caus
sever
diseas
although
data
conclus
type
may
exist
simultan
commun
infant
less
year
typic
shed
viru
day
children
immunodefi
cienci
may
shed
viru
month
immun
respons
vari
age
contribut
termin
diseas
patholog
featur
viru
transmit
respiratori
secret
close
contact
infect
person
contact
contamin
object
surfac
rsv
transmiss
rate
within
famili
onehalf
hospit
worker
acquir
rsv
therefor
hand
wash
wear
gown
glove
primari
import
attenu
transmiss
mortal
rsv
bronchiol
continu
declin
better
intens
care
use
prevent
therapi
male
infant
like
requir
hospit
usual
manifest
sever
diseas
infant
infect
rsv
bronchiol
year
life
hospit
hospit
infant
requir
mechan
ventil
antibodymedi
immun
rsv
introduc
onto
nasal
conjunctiv
mucos
surfac
caus
profus
rhinorrhea
within
day
fi
rst
month
life
passiv
acquir
matern
antibodi
protect
howev
matern
antibodi
titer
gradual
decreas
infant
becom
suscept
sever
diseas
cellbound
iga
may
develop
help
clear
viru
circul
igg
direct
glycoprotein
g
fusion
f
protein
oper
syncytia
format
viral
surfac
develop
sever
day
later
infant
less
month
age
appear
induc
weaker
antibodi
respons
like
due
presenc
matern
antibodi
virusspecifi
c
ige
respiratori
tract
associ
diseas
sever
often
complet
effect
immun
respons
induc
thu
reinfect
possibl
even
season
epitheli
cell
alveolar
macrophag
key
activ
cellular
immun
although
cell
enhanc
viral
clear
also
contribut
airway
infl
ammat
releas
cytokin
chemokin
includ
interleukin
il
tumor
necrosi
factoralpha
macrophageinfl
ammatori
protein
mip
rant
regul
upon
activ
normal
cell
express
secret
releas
cytokin
chemokin
believ
partial
respons
airway
infl
ammat
hyperreact
effect
mediat
persist
beyond
acut
infect
contribut
prolong
pulmonari
dysfunct
children
requir
mechan
ventil
lower
peripher
cell
count
compar
hospit
infant
requir
mechan
ventil
infant
demonstr
low
cell
prolif
respons
interferon
ifng
product
requir
initi
cellular
immun
length
time
requir
mechan
ventil
found
invers
relat
product
role
cytokin
profi
le
express
ifng
ratio
controversi
studi
ratio
decreas
polyclon
stimul
hospit
infant
rsv
howev
recent
studi
shown
normal
ratio
follow
polyclon
stimul
neutrophil
predomin
cell
found
airway
infant
rsv
bronchiol
elev
level
found
high
concentr
nasal
secret
infect
children
act
neutrophil
chemoattract
evid
cellular
induc
injuri
seen
postmortem
examin
peribronchi
lymphocyt
infi
ltration
bronchial
epitheli
necrosi
typic
present
infant
typic
present
tachypnea
rhinorrhea
cough
lowgrad
fever
irrit
poor
feed
vomit
respiratori
rate
greater
breath
per
minut
often
associ
room
air
satur
less
infant
may
also
tachycardia
mild
conjunct
otiti
media
pharyng
lowgrad
fever
usual
persist
day
addit
infant
may
develop
metabol
acidosi
poor
calor
fl
uid
intak
apnea
often
fi
rst
present
symptom
rsv
bronchiol
small
infant
etiolog
apnea
remain
unknown
howev
like
relat
immatur
respiratori
control
center
brainstem
incid
apnea
infant
bronchiol
approxim
heterogen
natur
rsv
induc
lung
diseas
caus
atelectasi
area
overdistens
other
chest
roentgenogram
often
show
hyperinfl
ation
fl
atten
diaphragm
patchi
peribronchi
infi
ltrate
atelectasi
especi
right
upper
lobe
often
seen
infant
may
high
lung
volum
function
residu
capac
often
twice
normal
decreas
dynam
complianc
increas
regul
infl
ammatori
cascad
releas
chemokin
cytokin
contributori
airway
infl
ammat
hyperreact
c
hapter
ac
ute
pu
lmonari
n
fection
airway
resist
lead
mark
increas
work
breath
often
wors
expir
lower
airway
obstruct
alter
ga
exchang
hypoxemia
secondari
ventilationperfus
mismatch
anatom
differ
young
infant
older
children
contribut
sever
diseas
young
due
highli
compliant
cartilagin
chest
wall
poor
thorac
musculatur
infant
chest
wall
diffi
culti
counter
lung
inher
tendenc
toward
collaps
lead
greater
propens
small
infant
toward
atelectasi
compar
older
children
absenc
effect
collater
ventil
infant
also
contribut
develop
atelectasi
impair
ga
exchang
cellular
debri
small
airway
peribronchi
edema
increas
airway
resist
lead
wheez
predomin
symptom
infant
despit
potenti
sever
impair
lung
function
hospit
infant
improv
within
day
typic
week
normal
respiratori
rate
oxygen
ventil
chest
radiograph
usual
normal
day
howev
infant
protract
cours
mild
respiratori
symptom
persist
month
viral
respiratori
infect
link
develop
asthma
later
childhood
tucson
children
respiratori
studi
group
prospect
follow
year
infant
bronchiol
found
increas
risk
subsequ
wheez
episod
infant
increas
risk
sever
rsv
diseas
chronic
lung
diseas
due
prematur
bronchopulmonari
dysplasia
cystic
fi
brosi
congenit
heart
diseas
immunodefi
cienci
children
cystic
fi
brosi
rsv
account
symptomat
infect
hospit
infant
less
year
infant
requir
mechan
ventil
studi
hospit
infant
congenit
heart
diseas
infect
rsv
requir
intens
care
receiv
mechan
ventil
die
children
undergon
hematopoiet
stem
cell
transplant
develop
rsv
infect
extrem
high
mortal
despit
mechan
ventil
antivir
therapi
environment
factor
crowd
passiv
exposur
tobacco
smoke
lack
breastfeed
associ
develop
sever
diseas
compar
nation
averag
nativ
american
alaskan
children
younger
year
age
higher
rate
infect
three
subtyp
human
parainfl
uenza
virus
frequent
isol
children
bronchiol
commonli
caus
croup
similar
rsv
cellmedi
hyperrespons
viral
antigen
virusspecifi
c
ige
respons
observ
children
parainfl
uenza
bronchiol
upper
airway
edema
concomit
obstruct
symptom
may
present
children
infect
parainfl
uenza
signifi
cant
likelihood
develop
asthma
later
life
human
metapneumovirus
hmpv
group
rna
virus
paramyxovirida
famili
identifi
ed
human
hmpv
appear
second
common
caus
bronchiol
children
throughout
world
major
children
born
matern
hmpv
specifi
c
igg
wane
around
month
age
age
fi
essenti
children
expos
hmpv
neutral
antibodi
hmpv
two
subgroup
b
group
sever
clinic
symptom
clinic
present
children
viru
similar
rsv
pulmonari
infl
ammat
gener
peak
day
includ
interstiti
edema
infl
ammatori
cell
infi
ltrate
bronchiol
alveoli
infl
ammatori
chang
persist
day
half
infect
children
month
age
infect
primarili
winter
month
human
bocaviru
hbov
recent
discov
amino
acid
sequenc
new
member
parvovirida
famili
found
close
relat
bovin
parvoviru
canin
minut
viru
henc
name
bocaviru
bo
bovin
ca
canin
detect
hbov
respiratori
tract
symptomat
children
absenc
detect
nonsymptomat
control
strongli
suggest
viru
role
respiratori
infect
children
coinfect
commonli
describ
sampl
remain
unclear
hbov
primari
pathogen
act
exacerb
viral
ill
pathogenesi
hbov
well
describ
high
occurr
wheez
lower
respiratori
tract
symptom
children
infect
viru
specul
viru
may
signifi
cant
contributor
asthma
exacerb
major
infect
children
rhinorrhea
cough
wheez
howev
diarrhea
report
children
children
high
viral
load
hbov
detect
serum
suggest
potenti
diseas
beyond
respiratori
tract
infl
uenza
includ
novel
infl
uenza
strain
infl
uenza
b
caus
clinic
pictur
consist
bronchiol
small
infant
virus
may
caus
sever
multisystem
diseas
discuss
greater
detail
viral
pneumonia
section
rapid
diagnost
assay
avail
earli
detect
mani
virus
older
assay
antigenbas
includ
indirect
immunofl
uorescencedirect
immunofl
uoresc
ifa
dfa
enzym
immunoassay
eia
optic
immunoassay
oia
neuraminidas
activ
assay
although
still
wide
use
inexpens
technic
simpl
low
specifi
citi
sensit
molecular
assay
becom
new
gold
standard
respiratori
viru
detect
replac
tissu
cultur
may
take
day
publish
sensit
specifi
citi
approach
compar
tissu
cultur
antigen
assay
assay
gener
use
polymeras
chain
reaction
pcr
amplifi
cation
signifi
cant
advanc
assay
made
simplifi
perform
assay
decreas
requir
time
import
caus
fals
neg
test
result
remain
poor
specimen
handl
inadequ
sampl
collect
aid
cohort
hospit
patient
serolog
detect
respiratori
virus
rare
clinic
use
regardless
viral
etiolog
bronchiol
support
care
remain
mainstay
treatment
supplement
humidifi
ed
oxygen
frequent
need
due
mani
infant
oblig
nasal
breather
frequent
nasal
suction
may
benefi
cial
maintain
unobstruct
upper
airway
affect
infant
child
often
unabl
take
adequ
fl
uid
complic
increas
insens
loss
respiratori
tract
henc
intraven
fl
uid
may
requir
infant
children
sever
respiratori
distress
kept
npo
event
respiratori
failur
ensu
endotrach
intub
requir
antibiot
routin
indic
previous
healthi
children
infect
rsv
progress
diseas
leukocytosi
persist
fever
consolid
radiograph
system
toxic
prompt
evalu
bacteri
coinfect
use
empir
antibiot
high
risk
patient
often
requir
close
monitor
care
intens
care
unit
includ
infant
less
week
age
infant
histori
prematur
congenit
heart
diseas
bronchopulmonari
dysplasia
immunodefi
cienci
neurolog
diseas
infant
rsv
bronchiol
typic
combin
hyperinfl
ation
pulmonari
infi
ltrate
support
therapi
mainstay
treatment
bronchiol
ribavirin
bronchodil
corticosteroid
shown
benefi
secondari
bacteri
infect
rare
atelectasi
therefor
one
mode
ventil
recommend
infant
noninvas
posit
pressur
niipp
mode
cpap
bipap
may
attempt
infant
primari
respiratori
embarrass
secondari
atelectasi
howev
may
suitabl
diseas
process
appear
sever
protract
prolong
use
nipp
may
make
feed
diffi
cult
caus
breakdown
facial
tissu
diffi
cult
maintain
without
signifi
cant
sedat
compromis
ventil
infant
requir
endotrach
intub
mode
mechan
ventil
tailor
predomin
lung
patholog
present
ie
atelectasi
versu
hyperinfl
ation
children
signifi
cant
air
trap
may
need
mechan
ventil
similar
child
asthma
provid
low
respiratori
rate
longer
inspir
exhal
time
typic
infant
lose
function
residu
capac
frc
atelectasi
alveolar
infi
ltrate
therefor
despit
air
trap
infant
often
need
peep
adjust
recruit
alveoli
return
frc
normal
set
elev
pulmonari
vascular
resist
pvr
may
occur
infant
congenit
heart
diseas
bronchopulmonari
dysplasia
lower
pvr
tradit
method
maintain
oxygen
deep
sedat
muscl
relax
even
nitric
oxid
may
indic
ribavirin
fdaapprov
antivir
drug
rsv
ribavirin
inhibit
viral
replic
activ
rsv
infl
uenza
b
adenovirus
hepat
virus
lower
respiratori
tract
diseas
ribavirin
typic
administ
via
aerosol
metaanalysi
studi
involv
ribavirin
discourag
consist
common
clinic
experi
ribavirin
improv
clinic
outcom
therapi
target
attenu
virusinduc
infl
ammatori
cascad
also
disappoint
corticosteroid
administr
associ
reduct
clinic
score
need
hospit
length
hospit
routin
use
corticosteroid
given
via
rout
intraven
enter
aerosol
indic
except
patient
preexist
chronic
lung
diseas
bronchodil
shown
clear
benefi
patient
acut
rsv
bronchiol
random
control
trial
involv
infant
evalu
effect
salbutamol
albuterol
bronchiol
show
effect
remain
three
studi
demonstr
small
transient
improv
acut
clinic
score
although
routin
use
bronchodil
therapi
recommend
becom
accept
practic
attempt
see
individu
infant
beta
agonist
respons
clinic
respons
seen
trial
beta
agonist
use
discontinu
fi
random
trial
involv
infant
evalu
effect
nebul
adrenalin
epinephrin
bronchiol
show
clinic
improv
reduct
oxygen
requir
respiratori
rate
wheez
decreas
pulmonari
vascular
resist
two
studi
show
lower
hospit
admiss
rate
earlier
discharg
cochran
systemat
review
suggest
potenti
benefi
epinephrin
administr
howev
subsequ
studi
support
routin
use
albuterol
clinic
trial
select
infant
seem
reason
nebul
hyperton
salin
use
treat
hospit
well
ambulatori
children
viral
bronchiol
variabl
success
recent
cochran
metaanalysi
nebul
hyperton
salin
shown
improv
clinic
score
decreas
hospit
durat
sever
studi
evalu
benefi
surfact
nitric
oxid
sever
respiratori
distress
result
inconclus
current
support
routin
use
heliox
mixtur
oxygen
helium
lower
viscos
air
use
success
case
airway
obstruct
croup
airway
surgeri
asthma
reduc
respiratori
effort
period
airway
compromis
sever
studi
shown
improv
respiratori
distress
score
patient
heliox
continu
posit
airway
pressur
obviat
need
intub
mechan
ventil
palivizumab
neutral
human
mous
monoclon
antibodi
direct
rsvf
glycoprotein
licens
food
drug
administr
fda
prematur
infant
infant
bronchopulmonari
dysplasia
random
doubl
blind
placebo
control
impactrsv
trial
involv
high
risk
infant
found
signifi
cant
reduct
hospit
except
rare
anaphylaxi
signifi
cant
advers
effect
observ
palivizumab
approv
use
infant
congenit
heart
diseas
cardiac
synagi
studi
group
includ
children
congenit
heart
diseas
random
doubl
blind
placebo
control
trial
found
rel
reduct
rsv
associ
hospit
death
attribut
palivizumab
sinc
cardiopulmonari
bypass
decreas
serum
drug
concentr
recommend
addit
dose
given
follow
surgeri
continu
protect
desir
palivizumab
administ
intramuscularli
mgkg
everi
day
total
fi
dose
rsv
season
gener
novemb
march
high
risk
infant
infant
children
develop
rsv
infect
continu
receiv
prophylaxi
follow
recoveri
natur
acquir
antibodi
fulli
protect
motavizumab
new
enhanc
potenc
human
rsv
monoclon
antibodi
demonstr
time
greater
neutral
activ
rsv
complet
phase
iii
trial
motavizumab
found
equal
palivizumab
prevent
rsv
hospit
superior
palivizumab
reduct
rsvspecifi
c
outpati
medic
attend
lower
respiratori
tract
infect
malri
pneumonia
describ
infl
ammatori
condit
lung
alveoli
compromis
aspir
foreign
matter
infl
ammatori
fl
uid
cellular
debri
infect
primari
caus
parenchym
injuri
lung
pathogen
includ
virus
bacteria
fungi
sign
symptom
pneumonia
nonspecifi
c
may
occult
young
infant
children
often
fever
chill
headach
malais
restless
irrit
gastrointestin
complaint
abdomin
pain
distent
emesi
may
also
present
young
children
symptom
often
preced
minor
upper
respiratori
tract
infect
character
lowgrad
fever
rhinorrhea
signifi
cant
involv
lower
respiratori
tract
tachypnea
dyspnea
cough
nasal
fl
are
grunt
retract
may
seen
older
child
may
demonstr
product
sputum
complain
pleurit
chest
pain
auscult
chest
rale
andor
decreas
breath
sound
might
heard
area
consolid
pleural
effus
howev
due
short
path
transmiss
breath
sound
small
chest
size
infant
breath
sound
may
decreas
even
presenc
effus
children
pleural
irrit
might
prefer
lie
affect
side
leg
fl
exe
may
complain
radiat
pain
neck
shoulder
abdomen
commun
acquir
pneumonia
cap
common
time
seriou
infect
children
incid
cap
case
per
children
less
year
age
case
per
children
year
age
exact
preval
etiolog
agent
caus
pediatr
pneumonia
diffi
cult
ascertain
often
diffi
cult
differenti
viral
bacteri
pneumonia
base
sole
clinic
examin
specifi
c
pathogen
caus
cap
determin
approxim
onethird
children
use
commonli
avail
cultur
antigen
detect
serolog
techniqu
blood
cultur
yield
pathogen
infant
children
bacteri
cap
mani
children
undergo
viral
test
often
unnecessari
inher
limit
gener
thought
virus
account
approxim
cap
children
age
year
approxim
cap
preschool
children
age
year
palivizumab
use
prevent
therapi
infant
chronic
lung
diseas
congenit
heart
diseas
cardiopulmonari
bypass
signifi
cantli
lower
serum
level
palivizumab
redos
follow
surgeri
continu
protect
desir
viral
caus
declin
school
age
adolesc
child
bacteri
caus
streptococcu
pneumonia
mycoplasma
becom
import
pathogen
fig
overal
bacteria
account
communityacquir
pneumonia
likelihood
infect
differ
bacteria
vari
age
newborn
period
organ
matern
genit
tract
like
caus
includ
group
b
streptococcu
escherichia
coli
enter
gramneg
bacilli
listeria
chlamydia
older
infant
streptococcu
pneumonia
becom
signifi
cant
caus
remain
year
age
group
streptococcu
staphylococcu
aureu
uncommon
caus
moraxella
catarrali
common
caus
upper
respiratori
tract
diseas
rare
caus
pneumonia
infant
pertussi
bacteri
coinfect
children
older
year
age
streptococcu
pneumonia
remain
common
caus
hemophilu
infl
uenza
type
b
hib
recent
streptococcu
pneumonia
decreas
signifi
cantli
caus
cap
due
widespread
use
effect
vaccin
older
child
young
adolesc
atyp
pneumonia
mycoplasma
chlamydia
becom
preval
viral
caus
less
common
rare
bacteri
pneumonia
occur
anim
contact
includ
francisella
tularensi
rabbit
chlamydia
psittaci
parrot
bird
coxiella
burnetii
sheep
salmonella
choleraesui
pig
children
congenit
anatom
defect
immunodefi
cienci
genet
disord
increas
risk
bacteri
viral
fungal
pneumonia
airway
normal
steril
sublaryng
area
lung
parenchyma
sever
protect
mechan
includ
anatom
mechan
factor
local
immun
defens
system
immun
respons
microb
fi
ltere
nasal
hair
expel
airway
epiglott
refl
ex
cough
refl
ex
mucociliari
apparatu
immunoglobulin
iga
predomin
immunoglobulin
present
upper
respiratori
tract
iga
abl
bind
two
antigen
simultan
form
larg
antigenantibodi
complex
manner
microb
neutral
remov
ciliari
clearanc
thu
prevent
microbi
bind
epithelium
lower
tract
immunoglobulin
g
igg
provid
humor
protect
opson
microb
phagocytosi
neutrophil
macrophag
activ
complement
cascad
neutral
bacteri
diffi
cult
determin
etiolog
agent
caus
pneumonia
microbi
agent
identifi
ed
bacteria
isol
etiolog
commun
acquir
pneumonia
base
age
endotoxin
alveolar
macrophag
produc
superoxid
anion
hydrogen
peroxid
hydroxyl
radic
serv
import
role
host
defens
howev
uncontrol
product
lead
lung
injuri
addit
oxygen
radic
number
cytokin
produc
alveolar
macrophag
includ
tnf
transform
growth
tgfb
chemotact
factor
platelet
deriv
growth
factor
mcsf
cytokin
play
central
role
phagocyt
recruit
activ
infect
occur
one
defens
mechan
alter
inoculum
larg
pathogen
typic
gain
entri
inhal
aerosol
materi
aspir
resist
organ
inhabit
upper
airway
less
frequent
pneumonia
occur
via
hematogen
spread
children
bacteri
pneumonia
signifi
cant
portion
concurr
preced
viral
infect
viral
infect
may
predispos
bacteri
superinfect
reduc
clearanc
mechan
weaken
host
immun
respons
pathogen
enter
lower
airway
evok
exud
consolid
pulmonari
tissu
initi
hyperemia
lung
parenchyma
due
vascular
engorg
capillari
leak
caus
exud
intraalveolar
fl
uid
accumul
fibrin
deposit
airway
infi
ltrate
neutrophil
consolid
caus
decreas
lung
complianc
vital
capac
total
reduct
surfac
area
avail
ga
exchang
physiolog
shunt
vq
mismatch
occur
increas
blood
fl
ow
poorli
ventil
segment
lung
result
hypoxia
compensatori
hypox
vasoconstrict
may
occur
attempt
reduc
vq
mismatch
hypoxia
especi
local
area
consolid
treatment
resolut
consolid
occur
day
exud
undergo
enzymat
digest
either
reabsorb
remov
cough
bacteri
infect
extend
pleural
caviti
empyema
may
result
streptococcu
pneumonia
gramposit
diplococcu
frequent
found
upper
respiratori
tract
capsular
serotyp
infect
caus
serotyp
common
bacteri
caus
pneumonia
occur
peak
age
month
typic
caus
lobar
segment
consolid
may
manifest
patchi
infi
ltrate
infant
pleural
effus
occur
children
requir
hospit
fig
pneumatocoel
format
rare
hemolyt
urem
syndrom
associ
neuraminidaseproduc
strain
treatment
typic
penicillin
cephalosporin
emerg
resist
may
requir
initi
therapi
vancomycin
hospit
patient
parenter
therapi
gener
need
h
fever
resolv
follow
complet
day
enter
therapi
pneumococc
conjug
vaccin
pcv
develop
confer
immun
serotyp
pcv
prevnar
licens
use
unit
state
pcv
recent
introduc
replac
pcv
pcv
highli
effect
reduc
hospit
among
children
younger
year
pneumococc
pneumonia
pcv
recommend
univers
children
younger
month
age
older
children
high
risk
due
underli
diseas
high
risk
children
includ
sickl
cell
diseas
type
function
asplenia
human
immunodefi
cienci
syndrom
primari
immunodefi
cienci
children
receiv
immunosuppress
therapi
children
chronic
pulmonari
cardiac
diseas
pcv
avail
pneumonia
occur
one
host
defens
mechan
alter
virus
enhanc
host
suscept
bacteri
pathogen
affect
clear
mechan
weaken
host
immun
respons
streptococcu
pneumonia
common
bacteri
caus
pneumonia
c
hapter
ac
ute
pu
lmonari
n
fection
high
risk
children
need
expand
serotyp
coverag
children
sickl
cell
diseas
function
asplenia
continu
receiv
antibiot
prophylaxi
regardless
whether
receiv
pneumococc
vaccin
approxim
infant
born
chlamydia
trachomati
infect
mother
becom
infect
one
anatom
site
includ
conjunctiva
nasopharynx
rectum
vagina
infant
nasopharyng
infect
develop
pneumonia
infant
usual
present
week
age
cough
congest
absenc
fever
cough
often
interfer
abil
feed
infant
gener
tachypnea
rale
examin
chest
xray
frequent
show
hyperinfl
ation
peripher
eosinophilia
may
present
c
trachomati
suscept
macrolid
tetracyclin
quinolon
sulfonamid
erythromycin
week
treatment
choic
neonat
pneumonia
mycoplasma
pneumonia
chlamydia
pneumonia
play
greater
role
caus
respiratori
tract
diseas
children
previous
thought
indol
cours
develop
day
manifest
lowgrad
fever
scratchi
sore
throat
ach
headach
character
pathogen
day
rale
may
heard
particularli
base
infi
ltrate
tend
occur
organ
associ
initi
promot
exacerb
asthma
children
addit
pertussislik
ill
acut
bronchiti
describ
recent
studi
shown
nearli
half
case
communityacquir
pneumonia
children
age
year
associ
pneumonia
c
pneumonia
classic
atyp
pneumonia
caus
organ
usual
mild
selflimit
howev
number
studi
suggest
sever
pulmonari
infect
may
occur
otherwis
healthi
children
pleural
effus
pneumatocoel
lung
abscess
pneumothorac
bronchiectasi
chronic
interstiti
fi
brosi
acut
respiratori
distress
syndrom
although
rare
complic
report
serolog
test
common
mean
diagnosi
often
retrospect
cultur
obtain
swab
nasopharynx
may
take
sever
day
grow
pcr
techniqu
current
refi
ned
standard
treatment
antibiot
reduc
rate
recurr
wheez
episod
decreas
morbid
shorten
durat
symptom
organ
suscept
tetracyclin
macrolid
quinolon
optim
dose
durat
treatment
unclear
howev
data
suggest
prolong
treatment
greater
week
may
desir
decreas
symptom
erad
organ
nasopharynx
chlamydia
pneumonia
increas
preval
older
children
chest
radiograph
year
old
femal
streptococcu
pneumonia
pneumonia
note
combin
consolid
effus
affect
right
lung
imag
provid
courtesi
fa
maffei
staphylococcu
aureu
gramposit
organ
found
skin
nasal
mucosa
mucu
membran
children
carrier
gener
spread
direct
contact
respiratori
particl
aureu
unusu
caus
lower
airway
diseas
otherwis
healthi
children
typic
isol
infant
young
children
debilit
condit
primari
aureu
pneumonia
present
winter
earli
spring
short
febril
prodrom
rapid
onset
pulmonari
symptom
blood
cultur
posit
patient
secondari
staphylococc
pneumonia
prolong
prodrom
season
predilect
often
seen
infl
uenza
infect
secondari
pneumonia
usual
result
hematogen
spread
blood
cultur
posit
patient
unilater
lobar
diseas
typic
primari
diseas
diffus
bilater
infi
ltrate
frequent
secondari
pneumonia
effus
diagnos
children
present
ultim
develop
case
pneumatocoel
occur
children
treatment
nafcillin
oxacillin
organ
becom
resist
requir
therapi
seriou
invas
diseas
vancomycin
linezolid
daptomycin
quinupristindalfopristin
methicillin
resist
staphylococcu
aureu
mrsa
consid
restrict
hospit
longterm
care
facil
howev
commun
acquir
mrsa
camrsa
signifi
cant
caus
varieti
infect
includ
pneumonia
children
without
prior
health
care
facil
exposur
major
commun
acquir
mrsa
infect
involv
minor
skin
soft
tissu
infect
invas
sometim
fatal
infect
occur
otherwis
healthi
individu
camrsa
healthcareassoci
mrsa
hamrsa
distinguish
sever
import
featur
patient
camrsa
defi
nition
recent
hospit
acut
chronic
care
prolong
antibiot
use
chronic
underli
diseas
toxin
product
also
distinguish
camrsa
hamrsa
panton
valentin
leukocidin
pvl
toxin
present
camrsa
isol
rare
hamrsa
isol
pvl
toxin
lyse
white
blood
cell
lead
leukopenia
decreas
abil
kill
aureu
product
implic
contributor
develop
camrsa
necrot
pneumonia
camrsa
isol
unlik
hamrsa
lack
multidrug
resist
camrsa
gener
suscept
clindamycin
trimethoprimsulfamethoxazol
doxycyclin
hamrsa
probabl
hamrsa
develop
resist
surviv
healthcar
set
group
betahemolyt
streptococcu
gabh
gramposit
organ
respons
pharyng
tonsil
children
rare
primari
caus
pneumonia
occur
children
gener
high
fever
appear
toxic
pneumonia
typic
lobar
associ
empyema
common
pneumatocoel
may
develop
sever
virul
toxinproduc
gabh
mserotyp
associ
toxic
shock
syndrom
preexist
varicella
diseas
disrupt
skin
soft
tissu
port
entri
report
approxim
time
associ
pneumonia
occur
children
toxic
shock
syndrom
gabh
highli
suscept
penicillin
cephalosporin
case
toxic
shock
clindamycin
often
ad
inhibit
product
streptococc
pyrogen
exotoxin
spea
b
speb
infant
perinat
acquir
group
b
streptococcu
gb
infect
pneumonia
infant
usual
system
diseas
blood
cultur
frequent
posit
lateonset
gb
predominantli
caus
type
iii
serotyp
infant
infect
usual
manifest
bacteremia
without
focu
mening
pneumonia
rare
lateonset
diseas
gb
uniformli
sensit
penicillin
staphylococcu
aureu
pneumonia
uncommon
effus
ultim
develop
case
pneumatocoel
occur
pertussi
whoop
cough
highli
contagi
respiratori
tract
infect
caus
gramneg
pleomorph
bacillu
bordetella
pertussi
less
commonli
bordetella
parapertussi
develop
widespread
use
vaccin
signific
sustain
decreas
incid
occur
howev
despit
immun
rate
greater
cyclic
recurr
diseas
occur
everi
year
sinc
like
secondari
wane
immun
adolesc
young
adult
underimmun
unimmun
infant
vulner
nearli
death
report
pertussi
occur
infant
younger
month
age
pertussi
often
divid
catarrah
fever
rhinnorhea
initi
cough
paroxysm
sever
cough
episod
lymphocytosi
potenti
complic
convalesc
stage
slow
wane
cough
week
month
complic
includ
secondari
bacteri
viral
pneumonia
apnea
malnutrit
pulmonari
hypertens
neurolog
involv
includ
seizur
encephalopathi
infant
less
month
age
highest
risk
complic
mortal
characterist
paroxysm
cough
end
inspiratori
whoop
occur
children
infant
may
present
nonspecifi
c
cough
associ
apnea
cyanosi
without
whoop
adolesc
may
asymptomat
mild
prolong
cough
increas
white
blood
count
lymphocytosi
characterist
earli
cours
diseas
prefer
test
laboratori
confi
rmation
detect
b
pertussi
dna
pcr
assay
bacteriolog
cultur
provid
defi
nitiv
diagnosi
administ
earli
stage
diseas
fi
rst
day
ill
erythromycin
day
may
decreas
symptom
reduc
risk
spread
day
cours
azithromycin
day
cours
clarithromycin
found
effect
less
gastrointestin
symptom
corticosteroid
bronchodil
intraven
immunoglobulin
demonstr
effi
caci
support
care
supplement
oxygen
mechan
ventil
intraven
fl
uid
mainten
adequ
calor
intak
treatment
secondari
bacteri
infect
mainstay
therapi
use
extracorpor
membran
oxygen
infant
hypoxemia
pulmonari
hypertens
right
heart
failur
refractori
convent
mechan
ventil
result
poorer
outcom
expect
vaccin
infanc
booster
dose
adolesc
prevent
pneumonia
children
caus
virus
consider
evid
viral
infect
often
preced
bacteri
pneumonia
caus
weaken
host
defens
viral
pneumonia
rsv
parainfl
uenza
discuss
detail
bronchiol
section
infl
uenza
main
viral
caus
pneumonia
schoolag
children
requir
hospit
three
serotyp
b
c
divid
subtyp
base
hemagglutinin
neuraminidas
gene
hemagglutinin
neuraminidas
typic
infect
human
gene
segment
surfac
glycoprotein
unstabl
mutat
call
antigen
shift
occur
regularli
epidem
occur
annual
winter
month
short
day
incub
period
viru
caus
destruct
ciliat
respiratori
epithelium
within
day
symptom
airway
edema
infi
ltration
infl
ammatori
cell
airway
mucosa
epithelium
follow
slow
repair
occur
week
sever
fulmin
pneumonia
may
result
hemorrhag
exud
contain
mani
polymorphonuclear
mononuclear
cell
destruct
respiratori
epithelium
often
lead
secondari
bacteri
infect
infl
uenza
season
infl
uenzarel
death
occur
children
less
year
age
fortyfi
percent
older
children
year
age
underli
medic
condit
rare
complic
although
death
infl
uenza
pneumonia
uncommon
signifi
cant
number
children
die
previous
healthi
infl
uenza
includ
acut
myositi
rhabdomyolysi
myocard
pericard
rey
syndrom
enceph
transvers
myeliti
syndrom
children
may
present
abrupt
clinic
cours
manifest
high
fever
myalgia
headach
scratchi
sore
throat
dri
cough
peripher
white
blood
count
usual
less
pulmonari
infi
ltrate
often
involv
multipl
lobe
bacteri
coinfect
especi
mrsa
increas
morbid
mortal
signifi
cantli
rimantidin
amantadin
shorten
cours
infl
uenza
type
diseas
limit
viral
replic
given
within
fi
rst
h
diseas
prophylact
dose
effect
interfer
antibodi
product
vaccin
drug
central
nervou
system
gastrointestin
side
effect
includ
increas
incid
seizur
oseltamivir
zanamivir
recent
approv
treatment
infl
uenza
infect
children
inhibit
neuraminidas
enzym
produc
infl
uenza
b
cours
diseas
healthi
adult
reduc
day
start
within
h
onset
symptom
zanamivir
dri
powder
aerosol
must
deliv
special
breathactiv
devic
bronchospasm
patient
asthma
report
aspirin
aspirincontain
product
avoid
due
risk
rey
syndrom
immunoprophylaxi
effect
strategi
prevent
infl
uenza
infect
inactiv
vaccin
effi
caci
rate
current
inactiv
vaccin
recommend
children
older
month
age
high
risk
condit
includ
chronic
pulmonari
cardiac
diseas
immunosuppress
disord
sickl
cell
diseas
hemoglobinopathi
diseas
requir
longterm
aspirin
therapi
chronic
metabol
renal
diseas
healthi
children
age
month
household
contact
age
month
high
risk
person
live
attenu
infl
uenza
vaccin
licens
administ
intranas
rout
approv
healthi
children
age
year
avian
infl
uenza
virus
normal
infect
speci
bird
pig
howev
fi
rst
human
death
avian
infl
uenza
occur
hong
kong
year
old
rey
syndrom
subsequ
epidem
occur
among
human
hong
kong
close
contact
live
infect
poultri
subtyp
appear
omin
due
abil
rapidli
mutat
infect
new
speci
overal
mortal
rate
greater
avian
virus
believ
transmiss
persontoperson
recent
case
investig
possibl
children
uniformli
present
fever
cough
symptom
rang
typic
infl
uenzalik
symptom
conjunct
respiratori
diseas
failur
signifi
cant
laboratori
data
includ
leukopenia
thrombocytopenia
children
develop
pneumonia
progress
ard
die
diagnosi
remain
diffi
cult
test
wide
avail
antivir
drug
avail
infl
uenza
recent
strain
southeast
asia
resist
rimantadin
amantadin
therefor
treatment
mainli
support
prototyp
vaccin
made
avail
manufactur
april
product
diffi
cult
standard
mean
produc
infl
uenza
vaccin
special
grown
chicken
egg
feasibl
kill
embryo
enough
virus
harvest
vaccin
product
april
center
diseas
control
confi
rmed
emerg
novel
infl
uenza
viru
gene
swine
virus
eurasian
lineag
gene
avian
infl
uenza
virus
june
fi
rst
infl
uenza
pandem
sinc
declar
affect
countri
territori
comparison
ill
season
infl
uenza
major
case
occur
individu
younger
year
age
nearli
half
case
occur
children
year
age
clinic
symptom
typic
infl
uenza
fever
sore
throat
cough
muscl
ach
addit
vomit
diarrhea
children
wide
rang
complic
although
antivir
medic
may
attenu
cours
infl
uenza
given
earli
immunoprophylaxi
vaccin
effect
strategi
control
infl
uenza
infect
avian
infl
uenza
occur
epidem
among
person
close
contact
live
infect
poultri
children
pneumonia
progress
ard
succumb
diseas
report
includ
mildtomoder
otiti
media
sinus
myositi
febril
seizur
sever
complic
myocard
rhabdomyolysi
enceph
sever
complic
may
frequent
involv
invas
bacteri
coinfect
ie
mrsa
andor
exacerb
underli
medic
condit
particular
asthma
children
present
initi
uncompl
infl
uenza
may
rapidli
progress
hypoxem
respiratori
failur
multiorgan
system
dysfunct
refractori
therapi
fig
report
death
approxim
children
major
children
comorbid
asthma
neurodevelopment
condit
obes
american
academi
pediatr
work
group
identifi
ed
children
greatest
risk
lifethreaten
infl
uenza
diseas
tabl
center
diseas
control
recommend
prompt
empir
antivir
therapi
infant
children
adolesc
age
present
suspect
confi
rmed
infl
uenza
follow
condit
ill
requir
hospit
progress
sever
complic
ill
regardless
previou
health
presenc
signifi
cant
risk
factor
see
tabl
strain
found
resist
amantadin
rimantadin
usual
sensit
neuraminidas
inhibitor
specifi
calli
oseltamivir
zanamir
oseltamivir
emerg
approv
treatment
children
less
month
age
resist
oseltamivir
report
thought
due
mutat
interestingli
mutat
confer
resist
oseltamivir
zanamivir
peramivir
neuraminidas
inhibitor
unapprov
investig
antivir
avail
intraven
formul
receiv
emerg
use
author
permit
fda
use
children
confi
rmed
sever
refractori
infl
uenza
use
restrict
children
respond
either
oral
inhal
antivir
drug
parenter
rout
depend
method
drug
deliveri
vaccin
manufactur
licens
use
standard
season
infl
uenza
late
singl
dose
found
provid
adequ
protect
children
older
year
age
younger
children
requir
two
dose
separ
least
day
adenovirus
implic
pneumonia
children
adenovirus
classifi
ed
serotyp
type
common
etiolog
agent
lower
respiratori
diseas
caus
sever
necrot
pneumon
serotyp
associ
seriou
pulmonari
sequela
bronchiectasi
bronchiol
obliteran
unilater
hyperluc
lung
persist
abnorm
pulmonari
function
test
adenoviru
infect
peak
month
year
age
mortal
sever
respiratori
infect
high
diseas
often
involv
multipl
organ
system
survivor
may
perman
lung
injuri
often
form
bronchiol
obliteran
immunocompromis
host
mortal
rate
high
cidofovir
vitro
activ
adenoviru
proof
effi
caci
limit
therapi
support
sever
acut
respiratori
syndrom
newli
describ
pulmonari
infect
caus
novel
sarsassoci
coronaviru
sarscov
highli
contagi
coin
fi
rst
plagu
twentyfi
rst
centuri
diseas
rapidli
spread
among
household
contact
healthcar
personnel
children
less
year
age
account
approxim
affect
mean
age
year
death
report
among
children
outbreak
children
adult
present
fever
malais
cough
coryza
chill
rigor
sputum
product
headach
myalgia
leukopenia
lymphopenia
thrombocytopenia
mildli
elev
activ
partial
thromboplastin
time
elev
level
lactat
dehydrogenas
radiograph
chest
show
nonspecifi
c
infi
ltrate
apart
diarrhea
patient
minim
extrapulmonari
symptom
earli
diagnosi
revers
transcriptionpolymeras
chain
reaction
rtpcr
made
sensit
nasopharyng
aspir
within
fi
rst
day
ill
clinic
cours
follow
triphas
pattern
incub
period
day
prodrom
high
fever
chill
malais
headach
myalgia
diarrhea
occur
adult
day
diseas
progress
involv
lower
airway
dri
nonproduct
cough
dyspnea
case
acut
respiratori
distress
syndrom
ard
follow
often
patient
requir
mechan
ventil
death
occur
respiratori
failur
young
children
run
milder
shorter
biphas
clinic
cours
cough
found
approxim
half
children
crackl
rare
heard
despit
radiograph
evid
infi
ltrate
regimen
antibiot
ribavirin
corticosteroid
propos
base
initi
anecdot
success
howev
ribavirin
demonstr
minim
activ
sarscov
isol
vitro
nonrandom
studi
corticosteroid
report
favor
outcom
pediatr
seri
children
confi
rmed
sar
treat
ribavirin
corticosteroid
show
advers
effect
surviv
mortal
adenoviru
infect
remain
high
multipl
organ
system
involv
sar
rare
affect
children
morbid
less
report
mortal
neurolog
disord
epilepsi
cerebr
palsi
development
delay
neuromuscular
disord
chronic
respiratori
diseas
associ
impair
pulmonari
function
andor
diffi
culti
handl
lung
secret
moder
especi
sever
persist
asthma
technologydepend
children
eg
requir
oxygen
tracheostomi
ventil
primari
immunodefi
cienci
condit
requir
medic
treatment
result
secondari
immunodefi
cienci
congenit
heart
diseas
metabol
eg
mitochondri
endocrin
disord
especi
cardiopulmonari
function
impair
adapt
http
wwwaaporgnewswinefl
uhtm
hantaviru
cardiopulmonari
syndrom
viral
zoonot
diseas
affect
healthi
children
adolesc
expos
aerosol
rodent
excreta
deer
mous
main
rodent
reservoir
case
occur
southwestern
unit
state
case
confi
rmed
state
hcp
present
prodrom
fever
chill
myalgia
headach
gastrointestin
symptom
respiratori
compromis
requir
supplement
oxygen
gener
occur
within
h
diseas
progress
respiratori
distress
ard
major
death
result
hypoxemia
cardiac
dysfunct
mark
hypotens
ventricular
arrhythmia
adult
case
fatal
rate
approxim
recent
case
seri
children
age
year
reveal
infect
children
develop
hcp
die
critic
ill
requir
mechan
ventil
treatment
support
ribavirin
proven
reduc
mortal
extracorpor
membran
oxygen
use
two
patient
one
surviv
laboratori
evalu
reveal
thrombocytopenia
leukocytosi
circul
immunoblast
elev
prothrombin
time
predict
sever
diseas
death
report
children
younger
year
age
diagnosi
made
detect
hantavirusspecifi
c
immunoglobulin
hantavirusspecifi
c
rna
polymeras
chain
reaction
hantaviru
antigen
immunohistochemistri
respiratori
infect
children
primari
acquir
immunodefi
cienci
requir
intens
care
uncommon
infant
children
suscept
mani
organ
rare
pathogen
normal
host
primari
immunodefci
includ
abnorm
defi
cienci
immunoglobulin
antibodi
b
cell
phagocyt
natur
killer
cell
complement
acquir
immunodefi
cienci
includ
asplenia
human
immunodefi
cienci
viru
hiv
corticosteroid
therapi
immunosuppres
use
marrow
solid
organ
transplant
immunocompromis
children
present
attenu
sign
symptom
respiratori
infect
addit
physic
examin
chest
roentgenogram
children
often
requir
chest
comput
tomographi
better
delin
extent
diseas
bronchoalveolar
lavag
needl
aspir
lung
biopsi
might
requir
make
defi
nitiv
diagnosi
pulmonari
specimen
test
common
bacteria
well
pneumocysti
carinii
acidfast
bacilli
nocardia
legionella
crytococcu
aspergillu
candida
histoplasma
coccidioid
blastomyc
virus
cytomegaloviru
varicella
herp
viru
measl
consid
pneumocysti
carinii
known
pneumocysti
jiroveci
opportunist
pulmonari
pathogen
infant
children
human
immunodefi
cienci
viru
hiv
primari
immunodefi
cienci
malnutrit
hematolog
malign
solid
organ
bone
marrow
transplant
recipi
patient
high
dose
corticosteroid
therapi
infl
ammatori
collagenvascular
diseas
unicellular
organ
exist
cyst
diagnost
form
organ
attach
type
alveolar
cell
result
alveol
character
ventilationperfus
mismatch
decreas
pulmonari
complianc
untreat
pcp
carri
mortal
rate
nearli
hivseroposit
child
fortun
incid
markedli
decreas
administr
chemoprophylact
agent
high
risk
patient
children
typic
present
fever
tachypnea
nonproduct
cough
hypoxia
absenc
rale
auscult
chest
initi
may
elev
ph
low
carbon
dioxid
level
lactat
dehydrogenas
level
gener
elev
bilater
diffus
alveolar
infi
ltrate
seen
initi
hilar
involv
subsequ
spread
peripheri
fig
diagnosi
made
demonstr
organ
methenamin
silver
nitrat
stain
pulmonari
tissu
respiratori
secret
lung
fl
uid
bronchoalveolar
lavag
wide
use
techniqu
obtain
lung
fl
uid
diagnosi
treatment
consist
support
therapi
hantaviru
rare
infant
schoolag
children
death
report
children
less
year
age
supplement
oxygen
ultim
continu
posit
airway
pressur
mechan
ventil
may
necessari
respiratori
failur
occur
trimethoprimsulfamethoxazol
tmpsmx
recommend
initi
treatment
patient
toler
tmpsmx
pentamidin
isoethion
use
corticosteroid
antiinfl
ammatori
dose
adjunct
antimicrobi
therapi
improv
clinic
outcom
concurr
pulmonari
infect
found
patient
frequent
bacteri
cytomegaloviru
pneumonia
determin
etiolog
agent
pneumonia
diffi
cult
fortun
communityacquir
pneumonia
identifi
cation
specifi
c
caus
organ
critic
howev
children
complic
cours
fail
respond
standard
therapi
defi
nitiv
diagnosi
etiolog
agent
essenti
complet
blood
count
infl
ammatori
marker
chest
radiograph
differenti
caus
agent
pneumonia
blood
cultur
rare
posit
outsid
neonat
period
rapid
antigen
test
avail
rsv
parainfl
uenza
infl
uenza
adenoviru
nasopharyng
swab
viral
cultur
gener
take
day
becom
posit
one
studi
patient
discharg
prior
posit
result
older
children
adolesc
might
abl
produc
sputum
gram
stain
cultur
adequ
specimen
contain
leukocyt
fewer
squamou
epitheli
cell
per
lowpow
fi
eld
intub
patient
sputum
easili
acquir
howev
interpret
result
gram
stain
cultur
time
diffi
cult
differenti
colon
patholog
organ
colon
endotrach
tube
may
occur
earli
h
frequent
h
oropharynx
becom
colon
within
h
stomach
h
lower
respiratori
tract
h
addit
comparison
infecti
agent
isol
tracheal
aspir
bronchoalveolar
lavag
found
concord
bronchoalveolar
lavag
bal
safe
use
obtain
secret
lower
airway
gram
stain
cultur
especi
use
diagnosi
pneumonia
immunocompromis
child
howev
bal
perform
directli
bronchoscop
carri
risk
contamin
smallest
bronchoscop
accommod
protect
specimen
brush
mm
requir
mm
endotrach
tube
passag
smallest
fl
exibl
fi
beropt
bronchoscop
suction
channel
extern
chest
radiograph
sever
pneumocysti
carinii
pneumonia
month
old
male
combin
immunodefi
cienci
note
diffus
alveolar
involv
air
bronchogram
imag
provid
courtesi
fa
maffei
diamet
mm
small
admit
doublesheath
brush
nonbronchoscop
doublelumen
plug
cathet
insert
blindli
endotrach
tube
obtain
noncontamin
specimen
sensit
specifi
citi
sampl
similar
obtain
bronchoscop
guid
protect
specimen
transthorac
needl
aspir
perform
center
good
result
one
studi
report
diagnost
success
rate
patient
incid
pneumothorax
approxim
none
requir
subsequ
placement
pleural
drainag
cathet
lung
biopsi
rare
need
make
defi
nitiv
diagnosi
support
treatment
oxygen
intraven
fl
uid
often
standard
therapi
pneumonia
mechan
ventil
caus
elev
antidiuret
hormon
level
care
fl
uid
monitor
essenti
avoid
overhydr
excess
lung
water
hyponatremia
initi
antibiot
choic
empir
base
upon
like
organ
age
group
diffi
culti
identifi
caus
agent
child
respiratori
statu
includ
respiratori
rate
work
breath
puls
oximetri
central
nervou
system
respons
close
monitor
noninvas
bilevel
posit
airway
pressur
bipap
effect
use
children
mild
moder
respiratori
insuffi
cienci
defi
ned
aa
gradient
pao
fio
ratio
mm
hg
serial
evalu
maskfac
contact
area
essenti
avoid
skin
breakdown
children
moder
sever
respiratori
insuffi
cienci
often
requir
intub
mechan
ventil
children
respiratori
failur
secondari
pneumonia
often
requir
increas
posit
end
expiratori
pressur
peep
increas
inspiratori
time
aggress
pulmonari
toilet
recruit
alveoli
patient
requir
high
level
peep
adequ
sedat
often
requir
prevent
patientventil
asynchroni
barotrauma
spontan
respir
encourag
mechan
ventil
rare
use
neuromuscular
blockad
requir
allow
mechan
ventil
prone
posit
may
improv
ventilationperfus
vq
mismatch
depend
lung
region
lung
protect
strategi
allow
permiss
hypercapnea
small
lung
volum
ventil
appropri
peep
maintain
alveolar
recruit
recommend
children
pneumonia
high
frequenc
oscillatori
ventil
also
util
maintain
mean
airway
pressur
alveolar
recruit
airway
pressur
releas
ventil
aprv
provid
recruit
alveoli
allow
spontan
respir
children
sever
respiratori
distress
syndrom
treatment
bovin
surfact
may
improv
oxygen
extracorpor
life
support
continu
role
children
revers
sever
acut
hypoxem
respiratori
failur
refractori
mechan
ventil
pneumonia
often
complic
develop
pleural
effus
empyema
occur
fl
uid
product
interstiti
lung
tissu
exce
maximum
pleural
lymphat
fl
ow
parapneumon
effus
often
occur
pneumonia
white
blood
cell
debri
infect
block
lymphat
result
elev
protein
pleural
space
increas
colloid
osmot
pressur
consequ
failur
fl
uid
reabsorpt
physic
exam
child
decreas
breath
sound
effus
older
children
auscultatori
percuss
chang
might
appreci
plain
chest
radiograph
reveal
clinic
signifi
cant
effus
ultrasound
chest
comput
tomogram
use
determin
volum
qualiti
fl
uid
presenc
locul
simpl
parapneumon
effus
transud
also
differenti
exud
use
criteria
light
et
al
tabl
pleural
fl
uid
ph
less
indic
complic
effus
like
exud
requir
drainag
wherea
pleural
fl
uid
ph
suggest
effus
may
manag
system
antibiot
alon
complic
parapneumon
effus
empyema
occur
fl
uid
becom
purul
stage
effus
undergo
fi
brinopurul
stage
mani
polymorphonuclear
leukocyt
bacteria
cellular
debri
enter
fl
uid
fibrin
deposit
pleural
surfac
locul
begin
form
ph
glucos
level
fall
ldh
level
rise
untreat
often
progress
third
organ
stage
exud
noninvas
bipap
ventil
effect
children
moder
respiratori
insuffi
cienci
develop
inelast
fi
brotic
peel
restrict
lung
simpl
parapneumon
effus
usual
resolv
thoracentesi
tube
thoracostomi
antibiot
treatment
pneumonia
complic
parapneumon
effus
success
treat
thoracotomi
tube
fi
brinolyt
howev
although
risk
bleed
reportedli
low
therapi
requir
close
monitor
chest
tube
drainag
instil
expens
medic
intermitt
clamp
chest
tube
singl
recommend
choic
fi
brinolyt
agent
dosag
establish
also
tri
late
organ
phase
often
unsuccess
due
locul
high
viscos
purul
fl
uid
surgic
debrid
either
open
procedur
videoassist
thorascop
surgeri
vat
often
need
organ
complic
parapneumon
effus
multipl
studi
report
earli
vat
thoracotomi
empyema
lead
shorter
hospit
stay
treatment
modal
best
determin
tempor
stage
natur
effus
acut
pulmonari
infect
common
diagnos
requir
admiss
pediatr
intens
care
unit
understand
pathophysiolog
lower
respiratori
infect
enabl
intensivist
tailor
therapi
individu
child
pathogen
earli
establish
specifi
c
etiolog
select
correct
treatment
plan
directli
impact
clinic
outcom
videoassist
thorascop
surgeri
vat
treatment
empyema
associ
shorter
hospit
stay
follow
therapi
proven
consist
benefi
rsv
bronchiol
aminophyllin
b
bronchodil
c
corticosteroid
ribavirin
e
support
care
palivizumab
indic
follow
children
month
old
former
week
prematur
infant
underw
surgic
repair
larg
ventricular
septal
defect
receiv
palivizumab
week
ago
b
month
old
former
week
prematur
infant
mild
bronchopulmonari
dysplasia
receiv
palivizumab
week
ago
c
month
old
former
week
prematur
infant
peripher
pulmon
stenosi
never
receiv
palivizumab
month
old
full
term
infant
urea
cycl
defect
never
receiv
palivizumab
e
month
old
former
week
prematur
infant
bronchopulmonari
dysplasia
receiv
fi
fth
dose
palivizumab
month
ago
pleural
fl
uid
may
classifi
ed
exud
one
follow
criteria
met
pleural
fl
uid
protein
divid
serum
protein
sensit
specifi
citi
pleural
fl
uid
lactat
dehydrogenas
ldh
divid
serum
ldh
sensit
specifi
citi
pleural
fl
uid
ldh
twothird
upper
limit
normal
serum
ldh
sensit
specifi
citi
adapt
light
